255 related articles for article (PubMed ID: 29391042)
1. Economic evaluations of lymphatic filariasis interventions: a systematic review and research needs.
Gedge LM; Bettis AA; Bradley MH; Hollingsworth TD; Turner HC
Parasit Vectors; 2018 Feb; 11(1):75. PubMed ID: 29391042
[TBL] [Abstract][Full Text] [Related]
2. Health economic analyses of the Global Programme to Eliminate Lymphatic Filariasis.
Turner HC
Int Health; 2020 Dec; 13(Suppl 1):S71-S74. PubMed ID: 33349885
[TBL] [Abstract][Full Text] [Related]
3. Elimination of lymphatic filariasis: do we have the drugs to complete the job?
Bockarie MJ; Deb RM
Curr Opin Infect Dis; 2010 Dec; 23(6):617-20. PubMed ID: 20847694
[TBL] [Abstract][Full Text] [Related]
4. The economic benefits resulting from the first 8 years of the Global Programme to Eliminate Lymphatic Filariasis (2000-2007).
Chu BK; Hooper PJ; Bradley MH; McFarland DA; Ottesen EA
PLoS Negl Trop Dis; 2010 Jun; 4(6):e708. PubMed ID: 20532228
[TBL] [Abstract][Full Text] [Related]
5. Evolution of the monitoring and evaluation strategies to support the World Health Organization's Global Programme to Eliminate Lymphatic Filariasis.
Lammie PJ; Gass KM; King J; Deming MS; Addiss DG; Biswas G; Ottesen EA; Henderson R
Int Health; 2020 Dec; 13(Suppl 1):S65-S70. PubMed ID: 33349883
[TBL] [Abstract][Full Text] [Related]
6. Towards elimination of lymphatic filariasis in India.
Das PK; Ramaiah KD; Augustin DJ; Kumar A
Trends Parasitol; 2001 Oct; 17(10):457-60. PubMed ID: 11587940
[TBL] [Abstract][Full Text] [Related]
7. Mass drug administration to eliminate lymphatic filariasis in India.
Ramaiah KD; Das PK
Trends Parasitol; 2004 Nov; 20(11):499-502. PubMed ID: 15471698
[TBL] [Abstract][Full Text] [Related]
8. Assessing progress in reducing the at-risk population after 13 years of the global programme to eliminate lymphatic filariasis.
Hooper PJ; Chu BK; Mikhailov A; Ottesen EA; Bradley M
PLoS Negl Trop Dis; 2014 Nov; 8(11):e3333. PubMed ID: 25411843
[TBL] [Abstract][Full Text] [Related]
9. A refined and updated health impact assessment of the Global Programme to Eliminate Lymphatic Filariasis (2000-2020).
Turner HC; Ottesen EA; Bradley MH
Parasit Vectors; 2022 May; 15(1):181. PubMed ID: 35643508
[TBL] [Abstract][Full Text] [Related]
10. The role of medicine donations in the global programme for the elimination of lymphatic filariasis.
Williams T; Taylor R; Iwamoto M; Hida T; Gusovsky F
Int Health; 2020 Dec; 13(Suppl 1):S39-S43. PubMed ID: 33349878
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic tools for filariasis elimination programs.
Weil GJ; Ramzy RM
Trends Parasitol; 2007 Feb; 23(2):78-82. PubMed ID: 17174604
[TBL] [Abstract][Full Text] [Related]
12. How Thailand eliminated lymphatic filariasis as a public health problem.
Rojanapanus S; Toothong T; Boondej P; Thammapalo S; Khuanyoung N; Santabutr W; Prempree P; Gopinath D; Ramaiah KD
Infect Dis Poverty; 2019 May; 8(1):38. PubMed ID: 31130143
[TBL] [Abstract][Full Text] [Related]
13. How much will it cost to eradicate lymphatic filariasis? An analysis of the financial and economic costs of intensified efforts against lymphatic filariasis.
Kastner RJ; Sicuri E; Stone CM; Matwale G; Onapa A; Tediosi F
PLoS Negl Trop Dis; 2017 Sep; 11(9):e0005934. PubMed ID: 28949987
[TBL] [Abstract][Full Text] [Related]
14. Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis.
Macfarlane CL; Budhathoki SS; Johnson S; Richardson M; Garner P
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD003753. PubMed ID: 30620051
[TBL] [Abstract][Full Text] [Related]
15. The health and economic benefits of the global programme to eliminate lymphatic filariasis (2000-2014).
Turner HC; Bettis AA; Chu BK; McFarland DA; Hooper PJ; Ottesen EA; Bradley MH
Infect Dis Poverty; 2016 May; 5(1):54. PubMed ID: 27388873
[TBL] [Abstract][Full Text] [Related]
16. Information technology in morbidity management of human lymphatic filariasis-A promising tool in global programme for elimination of lymphatic filariasis.
Devi RR; Raju V
J Vector Borne Dis; 2018; 55(1):20-25. PubMed ID: 29916444
[TBL] [Abstract][Full Text] [Related]
17. Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns.
Cano J; Basáñez MG; O'Hanlon SJ; Tekle AH; Wanji S; Zouré HG; Rebollo MP; Pullan RL
Parasit Vectors; 2018 Jan; 11(1):70. PubMed ID: 29382363
[TBL] [Abstract][Full Text] [Related]
18. Lymphatic filariasis in kenya since 1910, and the prospects for its elimination: a review.
Wamae CN; Mwandawiro C; Wambayi E; Njenga S; Kiliku F
East Afr Med J; 2001 Nov; 78(11):595-603. PubMed ID: 12219966
[TBL] [Abstract][Full Text] [Related]
19. Investment Success in Public Health: An Analysis of the Cost-Effectiveness and Cost-Benefit of the Global Programme to Eliminate Lymphatic Filariasis.
Turner HC; Bettis AA; Chu BK; McFarland DA; Hooper PJ; Mante SD; Fitzpatrick C; Bradley MH
Clin Infect Dis; 2017 Mar; 64(6):728-735. PubMed ID: 27956460
[TBL] [Abstract][Full Text] [Related]
20. The Global Programme to Eliminate Lymphatic Filariasis: health impact during its first 8 years (2000-2007).
Hooper PJ; Bradley MH; Biswas G; Ottesen EA
Ann Trop Med Parasitol; 2009 Oct; 103 Suppl 1():S17-21. PubMed ID: 19843394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
